Metabolic reprogramming is a hallmark of cancer, and it supports the increased energetic, biosynthetic, and redox demands associated with tumor development and progression. Therapeutic approaches exploiting differential metabolic requirements of tumor cells are in under investigation and in clinical trials. At the same time, mitochondrial toxicity has been implicated in clinical trial attrition and black box warnings, making predictive screening an important step in the drug development process.
Standard approaches to monitoring compound-induced metabolic perturbations rely on endpoint assays that provide limited kinetic information and lack cell-specific data in co-culture models. Live-cell analysis holds promise for greater physiological relevance and insight by providing the necessary tools to study dynamic cells changes in translational models.
This webinar, presented by Cicely Schramm, discusses:
Use of a live-cell approach to image and analyze intracellular ATP levels of cells in both mono and co-culture models, using the Incucyte® SX5 System
The value of live-cell ATP analysis to evaluate compound selectivity for development of novel therapeutics
Examination of stromal cell-mediated resistance in clinically relevant models
How direct, live-cell measurement of ATP can be implemented to screen for mitochondrial toxicity of drug candidates
Complete the form below to access the webinar.
Dr. Cicely Schramm
Manager of Biology
Product Development Cell Imaging
Dr. Cicely Schramm is the manager of the Ann Arbor-based biology team in the Cell Imaging Product Development group. The team focuses on the development of new reagents for the Incucyte® Live-Cell Analysis Systems.
Cicely is an experienced cell biologist with a multidisciplinary background spanning across academic, biotech, and pharmaceutical drug discovery environments. She received her PhD in neuroscience and completed her initial postdoctoral studies in cell signaling. She then studied tumor metabolism, focusing on non-essential amino acid requirements of cancer cells, prior to joining Essen Bioscience (now part of the Sartorius group) in 2016.